Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redefining the Conversion Mechanism of Chalcopyrite CuFeS<sub>2</sub> Electrodes for Li-Ion Battery via Multiscale Evolution Analysis.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Spatial Confinement-Accelerated DNAzyme Nanoassembly for Demethylase Imaging and Chemoresistance Evaluation in Living Cells.

ACS nano·2026
Same author

Optimization of Thulium Fiber Laser Lithotripsy Efficacy Based on Multidimensional Parameter Combination Strategies.

European urology open science·2026
Same author

Transcriptomic and metabolomic profiling to unravel sex-dependent mechanisms and the role of exogenous glutathione in Marchantia polymorpha under cadmium stress.

BMC plant biology·2026
Same author

FBXL6 promotes bladder cancer progression by stabilizing ENO1 through K63-linked ubiquitination.

Cell death discovery·2026
Same author

Characterization of Immune Infiltrating Cells in Bladder Urothelial Carcinoma and Its Clinical Significance.

Cancer medicine·2026

Related Experiment Video

Updated: Jun 5, 2025

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

10.3K

RRM2 Is a Putative Biomarker and Promotes Bladder Cancer Progression via PI3K/AKT/mTOR Pathway.

Linfa Guo1, Yiqiao Zhao1, Xiaojie Bai1

  • 1Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.

Journal of Cellular Physiology
|December 16, 2024
PubMed
Summary

Ribonucleotide reductase M2 (RRM2) is elevated in bladder cancer (BLCA), correlating with poor prognosis. Inhibiting RRM2 suppresses tumor growth and migration by impacting cell cycle and apoptosis via the PI3K/AKT/mTOR pathway.

Keywords:
AKTEMTRRM2bladder cancercell cyclemTOR

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K

Related Experiment Videos

Last Updated: Jun 5, 2025

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

10.3K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Bladder cancer (BLCA) presents significant challenges due to high recurrence and progression rates.
  • Identifying prognostic biomarkers is crucial for improving patient outcomes in BLCA.
  • Understanding the molecular mechanisms driving BLCA progression is imperative.

Purpose of the Study:

  • To investigate the prognostic significance and functional role of RRM2 in BLCA.
  • To elucidate the underlying molecular mechanisms by which RRM2 influences BLCA progression.
  • To evaluate RRM2 as a potential prognostic biomarker and therapeutic target for BLCA.

Main Methods:

  • Analysis of RRM2 expression in TCGA dataset and BLCA tissue microarrays.
  • In vitro assays (CCK8, colony formation, wound healing, Transwell) to assess RRM2's role in cell proliferation and migration.
  • Western blot and Gene Set Enrichment Analysis to investigate associated molecular pathways, including EMT, apoptosis, cell cycle, and PI3K/AKT/mTOR signaling.

Main Results:

  • RRM2 expression is significantly upregulated in BLCA tissues and cells.
  • Elevated RRM2 correlates with advanced tumor stage, higher grade, and poorer patient survival.
  • RRM2 knockdown inhibits BLCA cell proliferation and migration, induces apoptosis, and causes G0/G1 cell cycle arrest.
  • RRM2 promotes BLCA progression via activation of the PI3K/AKT/mTOR pathway.

Conclusions:

  • RRM2 is a significant oncoprotein in BLCA, associated with aggressive disease and poor prognosis.
  • RRM2 facilitates BLCA progression by promoting proliferation, migration, and inhibiting apoptosis and cell cycle arrest.
  • RRM2's role in activating the PI3K/AKT/mTOR pathway highlights its potential as a therapeutic target for BLCA.